1 / 4

Switch studies in virologically suppressed patients

Switch studies in virologically suppressed patients. Switch to TDF/FTC/EFV AI266-073 Switch to FTC + ddI + EFV ALIZE Switch to ATV/r-containing regimen ATAZIP Switch to ATV ± r-containing regimen SWAN SLOAT Switch to ATV-containing regimen ARIES INDUMA Switch to ATV/r monotherapy

moya
Télécharger la présentation

Switch studies in virologically suppressed patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Switch studies in virologically suppressed patients Switch to TDF/FTC/EFV AI266-073 Switch to FTC + ddI + EFV ALIZE Switch to ATV/r-containing regimen ATAZIP Switch to ATV±r-containing regimen SWAN SLOAT Switch to ATV-containing regimen ARIES INDUMA Switch to ATV/r monotherapy ATARITMO Swedish Study ACTG A5201 OREY Synopsis • Switch to LPV/r monotherapy • Pilot LPV/r • M03-613 • American Study • KalMo • OK • OK04 • KALESOLO • MOST • HIV-NAT 077 • Switch to DRV/r monotherapy • MONOI • MONET • Switch to RAL-containing regimen • Canadian Study • CHEER • Montreal Study • EASIER • SWITCHMRK • SPIRAL

  2. KalMo Study: Switch to LPV/r monotherapy • Design Randomisation 1 : 1 Open-label W96 N = 30 60 HIV+ ≥ 18 years On 2 NRTIs + (NNRTI or PI)> 6 months HIV-1 RNA < 80 c/mL > 6 months CD4 cell count > 200/mm3 N = 30 * 533/133 mg bid for the first 2 weeks if on NNRTI at screening • Endpoints • Primary endpoint: proportion of patients with HIV-1 RNA < 80 c/mLat W96 (ITT, missing equals failure analysis) • Secondary endpoints: virologic failure (2 consecutive HIV-1 RNA> 500 c/mL), AIDS-defining illnesses, CD4, safety, adverse events Nunes EP, HIV Clin Trials 2009;10:368-74 KalMo

  3. KalMo Study: Switch to LPV/r monotherapy Baseline characteristics and patient disposition Nunes EP, HIV Clin Trials 2009;10:368-74 KalMo

  4. KalMo Study: Switch to LPV/r monotherapy Virologic outcome Other outcomes • 1 virologic failure (confirmed HIV-1 RNA > 500 c/mL) in each group. No resistance mutation on genotype • No difference in CD4 changes between groups • GI adverse events more frequent in the monotherapy group: 24 vs 10(p = 0.001) • 5 patients in the triple therapy group underwent regimen changes due to drug-related toxicities • Conclusion: switching to LPV/r monotherapy is effective, safe and well tolerated through 96 weeks ITT analysis HIV-1 RNA < 80 c/mL On-treatment analysis* % 96 96 86.7 100 80 75 50 25 0 Triple therapy LPV/r mono * Includes only patients who completed 96 weeks of follow-up without discontinuation for other reasons than virologic failure Nunes EP, HIV Clin Trials 2009;10:368-74 KalMo

More Related